Human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma associated herpesvirus (KSHV), is an oncogenic virus that can cause Kaposi's sarcoma (KS). KS can develop following organ transplantation through reactivation of the recipient's latent HHV-8 infection, or less commonly through donor-derived infection which has higher risk for severe illness and mortality. We describe a case of probable donor-derived KS in the recipient of a liver-kidney transplant. The donor had multiple risk factors for infection. The KS was successfully treated by switching immunosuppression from tac- infection. Organs from this donor were transplanted into two recipients described below.
| Recipient1
A 56-year-old female underwent combined liver and right kid- 
| Recipient2
The recipient of the left kidney was a 62-year-old male with kidney failure secondary to diabetes mellitus. As of March, 2014 (10 months after surgery) there was no evidence of HHV-8 seroconversion or complications consistent with HHV-8 infection.
| HHV-8testing
To investigate whether the KS in Recipient 
| RESULTS
Retrospective testing of archived serum from the organ donor demonstrated strong reactivity for anti-HHV-8 antibody ( Table 1 ). The HHV 8 serologic testing for Recipient 1 showed that the pretransplant serum was negative for HHV-8 whereas the posttransplant serum revealed high titers of IgG antibody to HHV 8 further suggesting donorderived infection. HHV 8 serologic testing for Recipient 2 showed that both the pretransplant and posttransplant (10 months) serum specimens were negative for HHV-8 antibody (Table 1) .
| DISCUSSION
This case report describes the likely, though not confirmed, solid organ transplant transmission of HHV-8 from a seropositive deceased donor to a seronegative recipient and subsequent development of KS. Transplant-associated KS most often results from reactivation of HHV-8 in previously infected patients. 6, 7 Donor-derived KS is less common but results in more aggressive disease with higher rates of illness and mortality. [8] [9] [10] In the present case, it is more likely the 56-year-old female organ recipient acquired HHV-8 from the organ donor than other means. HHV-8 prevalence is low in the US general population at 3-6% 5 and concentrated in the MSM community where the prevalence is 15-25% among HIV-negative MSM, and 40-50% among HIV-positive MSM. 11, 12 Injection drug use is the other main risk factor for HHV-8 infection 13 but was unlikely the source in this case. ents. 16 The patient with KS in this report was successfully treated by switching from tacrolimus to sirolimus which studies have shown is associated with a lower incidence of malignancy in the posttransplant period. 17 The prevalence of posttransplant KS generally increases with the HHV-8 seroprevalence among donor and recipient populations. Europe. An appropriate screen test for HHV-8 would be antibody- The limited options for HHV-8 serology testing in the US underscores the need for a convenient and validated commercial assay.
Knowledge of the HHV-8 status of the donor and recipient could be beneficial to inform posttransplant patient care. This will require protocols to collect appropriate samples to be tested by laboratories with validated tests for HHV-8. Finally, there will be a need for collaboration between academic centers performing transplants, health departments, and federal authorities to coordinate and ensure that all recipients have been notified.
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